213 related articles for article (PubMed ID: 25179843)
21. Thymoquinone inhibits metastatic phenotype and epithelial‑mesenchymal transition in renal cell carcinoma by regulating the LKB1/AMPK signaling pathway.
Kou B; Kou Q; Ma B; Zhang J; Sun B; Yang Y; Li J; Zhou J; Liu W
Oncol Rep; 2018 Sep; 40(3):1443-1450. PubMed ID: 29956793
[TBL] [Abstract][Full Text] [Related]
22. The LKB1 tumor suppressor negatively regulates mTOR signaling.
Shaw RJ; Bardeesy N; Manning BD; Lopez L; Kosmatka M; DePinho RA; Cantley LC
Cancer Cell; 2004 Jul; 6(1):91-9. PubMed ID: 15261145
[TBL] [Abstract][Full Text] [Related]
23. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
24. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
Petrella BL; Brinckerhoff CE
Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma.
Li Y; Guan B; Liu J; Zhang Z; He S; Zhan Y; Su B; Han H; Zhang X; Wang B; Li X; Zhou L; Zhao W
EBioMedicine; 2019 Jun; 44():439-451. PubMed ID: 31130475
[TBL] [Abstract][Full Text] [Related]
26. Genetic alterations of the LKB1 gene in head and neck cancer.
Kenanli E; Karaman E; Enver O; Ulutin T; Buyru N
DNA Cell Biol; 2010 Dec; 29(12):735-8. PubMed ID: 20818976
[TBL] [Abstract][Full Text] [Related]
27. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
Meng J; Majidi M; Fang B; Ji L; Bekele BN; Minna JD; Roth JA
PLoS One; 2013; 8(10):e77067. PubMed ID: 24146957
[TBL] [Abstract][Full Text] [Related]
28. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.
Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ
Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328
[TBL] [Abstract][Full Text] [Related]
29. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology.
Green AS; Chapuis N; Lacombe C; Mayeux P; Bouscary D; Tamburini J
Cell Cycle; 2011 Jul; 10(13):2115-20. PubMed ID: 21572254
[TBL] [Abstract][Full Text] [Related]
30. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
31. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
32. Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel
Rodríguez-Moreno JF; Apellaniz-Ruiz M; Roldan-Romero JM; Durán I; Beltrán L; Montero-Conde C; Cascón A; Robledo M; García-Donas J; Rodríguez-Antona C
J Natl Compr Canc Netw; 2017 Nov; 15(11):1310-1315. PubMed ID: 29118224
[TBL] [Abstract][Full Text] [Related]
33. miR‑539 suppresses proliferation and induces apoptosis in renal cell carcinoma by targeting high mobility group A2.
Ye ZH; Gui DW
Mol Med Rep; 2018 Apr; 17(4):5611-5618. PubMed ID: 29436648
[TBL] [Abstract][Full Text] [Related]
34. miR-206 inhibits renal cell cancer growth by targeting GAK.
Wei C; Wang S; Ye ZQ; Chen ZQ
J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):852-858. PubMed ID: 27924503
[TBL] [Abstract][Full Text] [Related]
35. LncRNA TP73-AS1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Clear Cell Renal Cell Carcinoma Through Repressing KISS1 Expression and Inactivation of PI3K/Akt/mTOR Signaling Pathway.
Liu G; Zhao X; Zhou J; Cheng X; Ye Z; Ji Z
Cell Physiol Biochem; 2018; 48(1):371-384. PubMed ID: 30016766
[TBL] [Abstract][Full Text] [Related]
36. MiR-144 inhibits cell proliferation of renal cell carcinoma by targeting MTOR.
Xiang C; Cui SP; Ke Y
J Huazhong Univ Sci Technolog Med Sci; 2016 Apr; 36(2):186-192. PubMed ID: 27072960
[TBL] [Abstract][Full Text] [Related]
37. LKB1-AMPK axis revisited.
Kottakis F; Bardeesy N
Cell Res; 2012 Dec; 22(12):1617-20. PubMed ID: 22801477
[TBL] [Abstract][Full Text] [Related]
38. AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.
Liu JL; Mao Z; Gallick GE; Yung WK
Neuro Oncol; 2011 Feb; 13(2):184-94. PubMed ID: 21123367
[TBL] [Abstract][Full Text] [Related]
39. Association of Target Therapy Gene Expression with Metastasizing of Clear-Cell Renal Cell Carcinoma.
Apanovich NV; Peters MV; Apanovich PV; Markova AS; Kamolov BS; Matveev VB; Karpukhin AV
Bull Exp Biol Med; 2018 Dec; 166(2):257-259. PubMed ID: 30488209
[TBL] [Abstract][Full Text] [Related]
40. Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC).
Baumunk D; Reichelt U; Hildebrandt J; Krause H; Ebbing J; Cash H; Miller K; Schostak M; Weikert S
World J Urol; 2013 Oct; 31(5):1191-6. PubMed ID: 22544372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
